Literature DB >> 22284692

Polyglutamine neurodegeneration: expanded glutamines enhance native functions.

Harry T Orr1.   

Abstract

An intriguing set of neurodegenerative disease are the nine disorders caused by the expansion of a unstable trinucleotide CAG repeat where the repeat is located within the coding of the affected gene, that is, the polyglutamine (polyQ) diseases. A gain-of-function mechanism for toxicity in polyQ diseases is widely thought to have a major role in pathogenesis. Yet, the specific nature of this gain-of-function is a matter of considerable discussion. The basic issue concerns whether toxicity stems from the native or normal function of the affected protein versus a novel function induced by polyQ expansion. For at least three of the polyQ disease considerable evidence is accumulating that pathology is mediated by a polyQ-induced exaggeration of a native function of the host protein.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22284692      PMCID: PMC3340441          DOI: 10.1016/j.gde.2012.01.001

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  35 in total

1.  PolyQ disease: too many Qs, too much function?

Authors:  Ian H Kratter; Steven Finkbeiner
Journal:  Neuron       Date:  2010-09-23       Impact factor: 17.173

2.  Native functions of the androgen receptor are essential to pathogenesis in a Drosophila model of spinobulbar muscular atrophy.

Authors:  Natalia B Nedelsky; Maria Pennuto; Rebecca B Smith; Isabella Palazzolo; Jennifer Moore; Zhiping Nie; Geoffrey Neale; J Paul Taylor
Journal:  Neuron       Date:  2010-09-23       Impact factor: 17.173

3.  ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology.

Authors:  Yung C Lam; Aaron B Bowman; Paymaan Jafar-Nejad; Janghoo Lim; Ronald Richman; John D Fryer; Eric D Hyun; Lisa A Duvick; Harry T Orr; Juan Botas; Huda Y Zoghbi
Journal:  Cell       Date:  2006-12-29       Impact factor: 41.582

4.  Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila.

Authors:  Ken-ichi Takeyama; Saya Ito; Ayako Yamamoto; Hiromu Tanimoto; Takashi Furutani; Hirotaka Kanuka; Masayuki Miura; Tetsuya Tabata; Shigeaki Kato
Journal:  Neuron       Date:  2002-08-29       Impact factor: 17.173

Review 5.  Molecular mechanisms and potential therapeutical targets in Huntington's disease.

Authors:  Chiara Zuccato; Marta Valenza; Elena Cattaneo
Journal:  Physiol Rev       Date:  2010-07       Impact factor: 37.312

6.  A huntingtin-associated protein enriched in brain with implications for pathology.

Authors:  X J Li; S H Li; A H Sharp; F C Nucifora; G Schilling; A Lanahan; P Worley; S H Snyder; C A Ross
Journal:  Nature       Date:  1995-11-23       Impact factor: 49.962

7.  Huntingtin-associated protein 1 (HAP1) interacts with the p150Glued subunit of dynactin.

Authors:  S Engelender; A H Sharp; V Colomer; M K Tokito; A Lanahan; P Worley; E L Holzbaur; C A Ross
Journal:  Hum Mol Genet       Date:  1997-12       Impact factor: 6.150

Review 8.  Cerebellar development and disease.

Authors:  Kathleen J Millen; Joseph G Gleeson
Journal:  Curr Opin Neurobiol       Date:  2008-05-29       Impact factor: 6.627

9.  14-3-3 Binding to ataxin-1(ATXN1) regulates its dephosphorylation at Ser-776 and transport to the nucleus.

Authors:  Shaojuan Lai; Brennon O'Callaghan; Huda Y Zoghbi; Harry T Orr
Journal:  J Biol Chem       Date:  2011-08-11       Impact factor: 5.157

10.  Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment.

Authors:  Peggy C Nopoulos; Elizabeth H Aylward; Christopher A Ross; James A Mills; Douglas R Langbehn; Hans J Johnson; Vincent A Magnotta; Ronald K Pierson; Leigh J Beglinger; Martha A Nance; Roger A Barker; Jane S Paulsen
Journal:  Brain       Date:  2010-10-04       Impact factor: 13.501

View more
  38 in total

1.  A flexible polyglutamine hinge opens new doors for understanding huntingtin function.

Authors:  Flaviano Giorgini
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-23       Impact factor: 11.205

2.  A network of interdependent molecular interactions describes a higher order Nrd1-Nab3 complex involved in yeast transcription termination.

Authors:  Travis J Loya; Thomas W O'Rourke; Natalya Degtyareva; Daniel Reines
Journal:  J Biol Chem       Date:  2013-10-07       Impact factor: 5.157

Review 3.  Repeat associated non-ATG (RAN) translation: new starts in microsatellite expansion disorders.

Authors:  John Douglas Cleary; Laura P W Ranum
Journal:  Curr Opin Genet Dev       Date:  2014-05-22       Impact factor: 5.578

Review 4.  The role for alterations in neuronal activity in the pathogenesis of polyglutamine repeat disorders.

Authors:  Ravi Chopra; Vikram G Shakkottai
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

5.  Backbone Engineering within a Latent β-Hairpin Structure to Design Inhibitors of Polyglutamine Amyloid Formation.

Authors:  Karunakar Kar; Matthew A Baker; George A Lengyel; Cody L Hoop; Ravindra Kodali; In-Ja Byeon; W Seth Horne; Patrick C A van der Wel; Ronald Wetzel
Journal:  J Mol Biol       Date:  2016-12-13       Impact factor: 5.469

6.  Broad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: implications for spinocerebellar ataxia type 1 therapy.

Authors:  Megan S Keiser; Ryan L Boudreau; Beverly L Davidson
Journal:  Mol Ther       Date:  2013-12-12       Impact factor: 11.454

Review 7.  Tandem repeats mediating genetic plasticity in health and disease.

Authors:  Anthony J Hannan
Journal:  Nat Rev Genet       Date:  2018-02-05       Impact factor: 53.242

Review 8.  Modulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders.

Authors:  Sara D Reis; Brígida R Pinho; Jorge M A Oliveira
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

9.  Broad distribution of ataxin 1 silencing in rhesus cerebella for spinocerebellar ataxia type 1 therapy.

Authors:  Megan S Keiser; Jeffrey H Kordower; Pedro Gonzalez-Alegre; Beverly L Davidson
Journal:  Brain       Date:  2015-10-21       Impact factor: 13.501

10.  D-polyglutamine amyloid recruits L-polyglutamine monomers and kills cells.

Authors:  Karunakar Kar; Irene Arduini; Kenneth W Drombosky; Patrick C A van der Wel; Ronald Wetzel
Journal:  J Mol Biol       Date:  2013-11-28       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.